SCHEMBL5735574

SCHEMBL5735574

O=Cc1cccc(-c2ccc(F)c(F)c2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.54
TRIM33 Q9UPN9 1/20 0.54
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA9 Q16790 1/20 0.53
KIF11 P52732 1/20 0.46
ALDH1A1 P00352 2/20 0.44
NFE2L2 Q16236 1/20 0.43
DRD1 P21728 1/20 0.42
DYRK1A Q13627 1/20 0.42
DYRK2 Q92630 1/20 0.42
DYRK1B Q9Y463 1/20 0.42
ERN1 O75460 4/20 0.42
CDK8 P49336 1/20 0.42
BRD4 O60885 1/20 0.41
HSD17B1 P14061 1/20 0.41
HSD17B2 P37059 1/20 0.41
NPY5R Q15761 1/20 0.40
UNG P13051 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26704110 0.85 TRIM24 (0.50) TRIM24TRIM33CA12CA1CA2
SCHEMBL20395748 0.84 TRIM24 (0.50) TRIM24TRIM33CA12CA1CA2
SCHEMBL29955854 0.84 CA12 (0.53) TRIM24TRIM33CA12CA1CA2
SCHEMBL5734344 0.84 TRIM24 (0.50) TRIM24TRIM33CA12CA1CA2
SCHEMBL6619511 0.84 HSD17B1 (0.59) TRIM24TRIM33CA12CA1CA2
SCHEMBL11770226 0.83 TRIM24 (0.71) TRIM24TRIM33CA12CA1CA2
SCHEMBL346974 0.83 TRIM24 (0.64) TRIM24TRIM33CA12CA1CA2
SCHEMBL1854419 0.82 TRIM24 (0.61) TRIM24TRIM33CA12CA1CA2
SCHEMBL31558730 0.82 TRIM24 (0.61) TRIM24TRIM33CA12CA1CA2
SCHEMBL3457040 0.82 KIF11 (0.65) TRIM24TRIM33KIF11ALDH1A1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1244446-B1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2006-11-02 EP disclosed
US-6858630-B2 Naphthimidazole derivatives and their use as thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2005-02-22 US disclosed
US-20030083361-A1 Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia SMITHKLINE BEECHAM CORPORATION 2003-05-01 US disclosed
EP-1244446-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2003-01-08 EP disclosed
EP-1244446-A1 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2002-10-02 EP disclosed
WO-2001039773-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083361-A1 Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia MPL, THPO, TPO TRIM24 1668/4885TRIM33 1693/4885CA12 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.